Table 1 Representative compounds with enzymatic, antiviral, cell toxicity activity

From: Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19

Cpd. No.a

L

A

R1

R2

Purity (%)

PLpro IC50 (μM)

VeroE6 WT EC50 (μM) b

VeroE6 XBB EC50 (μM) b

VeroE6 Omic-BA.5 EC50 (μM) b

HEK293T CC50 (μM) b

GRL0617

99.77

4.8200

    

GNZL-P1

98.77

2.8310

-

-

-

-

GNZL-P2

98.42

6.9000

-

-

-

-

GNZL-P3

90.5

0.1858

-

-

-

-

GNZL-P4

98.96

0.0363

0.4

0.45

0.86

24.57

GNZL-P5

98.32

0.0210

-

-

-

-

GNZL-P13

93.37

0.0900

-

-

-

-

GNZL-P17

View full size image

92

0.00291

0.233

0.169

0.409

36.68

GNZL-P20

98.45

0.1150

-

-

-

-

GNZL-P25

93.1

0.4700

-

-

-

-

GNZL-P28

92

0.01464

-

-

-

-

GNZL-P29

95.46

0.0420

0.22

0.24

0.8

12.23

GNZL-P30

97.22

0.0440

-

-

-

-

GNZL-P31

View full size image

98.69

0.00846

0.035

0.042

0.174

157.4

GNZL-P35

98.26

0.00815

0.04

0.043

0.2

67.67

GNZL-P36

99.29

0.00645

0.111

0.058

0.306

88.41

  1. a Compound number; b “-” represents no data.
Back to article page